A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell …

R Sangha, R Jamal, J Spratlin, J Kuruvilla… - Investigational New …, 2024 - Springer
Myristoylation, the N-terminal addition of the fatty acid myristate to proteins, regulates
membrane-bound signal transduction pathways important in cancer cell biology. This …